SciELO - Scientific Electronic Library Online

 
vol.37 issue3Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic Primary Immune ThrombocytopeniaHow to prescribe for patients with dysphagia: a review for the adaptation of the pharmaceutical guide in a socio-sanitary hospital author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

GONZALEZ ALVAREZ, A.; GOMEZ BARRERA, M.; BORRAS BLASCO, J.  and  GINER SERRET, E. J.. Analisis of the budget impact of adalimumab and etanercept in rheumatoid arthritis and spondyloarthropathies. Farm Hosp. [online]. 2013, vol.37, n.3, pp.192-197. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.3.581.

Purpose: To assess the economic impact derived from the widening of the administration intervals of adalimumab (ADA) and etanercept (ETN) for the treatment of rheumatoid arthritis (RA) and spondyloarthropathies (SAP) at our working environment. Material and methods: A budget impact model (BIM) was developed to estimate the economic impact that would have widening the usual administration intervals of ADA, 40 mg every 2 weeks and ETN, 50 mg weekly (scenario A), to ADA, 40 mg every 3 weeks, and ETN, 50 mg every 2 weeks (scenario B) according to the guidelines and recommendations applied to these studies, specifying the target population, the study perspective, the temporal horizon, and analysing the study robustness by a threshold univariate sensitivity analysis. Results: 71 patients were included in the study. The application of the BIM showed yearly savings for ADA and ETN of 19.784 € and 38.271 €, respectively. The net cost, that is to say the saving that this would imply within the temporal horizon considered (2 years), was 116.110 €. The sensitivity analysis showed that the estimated BIM for the study period was very robust since the net result in the different scenarios varied very little, being negative in the new scenarios. Conclusions: widening the administration intervals of ADA and ETN to every 3 weeks and 2 weeks respectively, would be a strategy that would allow generating savings in the hospital budget close to 116.110 € for the temporal horizon considered, achieving this way optimization of the treatment with these two drugs.

Keywords : Rheumatoid arthritis; Spondyloarthropathies; Budget impact analysis; Adalimumab; Etanercept; Tumour necrosis factor inhibitors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License